- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01890538
Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo
Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo: A Double Blind Randomized Clinical Trial
This study aims to investigate efficacy of two different intravenous drugs (dimenhydrinate and piracetam) in the symptomatic management of peripheral vertigo.
The patients will be randomized in two groups according to symptomatic treatment modalities: Dimenhydrinate (100 mg) and piracetam (2 g) will be given in 100 cc normal saline in 30 minutes. Each patient will be asked if her/his vertigo symptoms resolved or not, according to a numeric rating scale (0=no vertigo, 10=worst possible vertigo). The patient will be rate the intensity of symptoms in the following times:
- Numeric rating scale (1 to 10): Admission
- Numeric rating scale (1 to 10): After the study drug (No ambulation)*
Numeric rating scale (1 to 10): After the study drug (Ambulation)*
- Ambulation refers to head movements or walking in the room, if applicable.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Kocaeli, Turkey, 41000
- Kocaeli University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Presenting to emergency department with vertigo symptoms
- Adult patients (over 18)
- Agree to participate to study (understanding the study protocol and signing the informed consent form)
Exclusion Criteria:
- Patients under 18 years
- Patients diagnosed with ischemic/hemorrhagic stroke after neuroimaging
- Patient diagnosed with transient ischemic attack
- Pregnants
- Patients taking any analgesics or antihistaminic drugs last 24 hours
- Documented or declared allergy to dimenhydrinate, piracetam or benzodiazepines
- Patients who do not agree to participate to the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Piracetam
2 g intravenous piracetam
|
|
Active Comparator: Dimenhydrinate
Dimenhydrinate 100 mg intravenous
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in numeric rating scale
Time Frame: Change from baseline in numeric rating scale at 30th minute
|
Change from baseline in numeric rating scale at 30th minute
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nurettin Özgür Doğan, M.D., Assistant Professor, Kocaeli University
Publications and helpful links
General Publications
- Scholtz AW, Schwarz M, Baumann W, Kleinfeldt D, Scholtz HJ. Treatment of vertigo due to acute unilateral vestibular loss with a fixed combination of cinnarizine and dimenhydrinate: a double-blind, randomized, parallel-group clinical study. Clin Ther. 2004 Jun;26(6):866-77. doi: 10.1016/s0149-2918(04)90130-0.
- Dogan NO, Avcu N, Yaka E, Yilmaz S, Pekdemir M. Comparison of the therapeutic efficacy of intravenous dimenhydrinate and intravenous piracetam in patients with vertigo: a randomised clinical trial. Emerg Med J. 2015 Jul;32(7):520-4. doi: 10.1136/emermed-2014-204006. Epub 2014 Jul 22.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Otorhinolaryngologic Diseases
- Labyrinth Diseases
- Ear Diseases
- Vestibular Diseases
- Sensation Disorders
- Vertigo
- Dizziness
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Neuroprotective Agents
- Protective Agents
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Nootropic Agents
- Dimenhydrinate
- Piracetam
Other Study ID Numbers
- KOU KAEK 2013/174
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Vertigo
-
University of CalgaryNot yet recruitingBPPV | Vertigo, Peripheral
-
Ankara City Hospital BilkentAnkara Training and Research HospitalCompletedOxidative Stress | Vertigo, Peripheral | Diagnosis | Vertigo, Central OriginTurkey
-
King Saud UniversityRecruitingMigraine | Vertigo | Vertigo, Peripheral | Vertigo LabyrinthineSaudi Arabia
-
Istanbul UniversityNot yet recruitingVertigo, Peripheral
-
Oman Medical Speciality BoardRecruiting
-
Shahid Beheshti University of Medical SciencesCompleted
-
National Taiwan University HospitalRecruiting
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruitingBPPV | Vertigo | Vertigo, PeripheralChina
-
University of MonastirNot yet recruiting
-
Apsen Farmaceutica S.A.Completed
Clinical Trials on 2 g piracetam intravenous
-
Epeius BiotechnologiesCompleted
-
Mansoura UniversityCompletedGallbladder and Bile Duct Calculi
-
Epeius BiotechnologiesTerminatedPancreatic CancerUnited States
-
Minia UniversityCompleted
-
Raisio GroupUniversity of TurkuCompletedDyslipidemias | Hypercholesterolemia | Hyperlipidemias
-
University of Novi Sad, Faculty of Sport and Physical...CarnoMedCompletedMultiple SclerosisSerbia
-
Mansoura UniversityCompleted
-
Rutgers, The State University of New JerseyRecruitingChronic Inflammatory Demyelinating Polyneuropathy | CIDP | Immunoglobulin DeficiencyUnited States
-
Hospital Civil de GuadalajaraNot yet recruitingArginine + Citrulline as a Supplement for Weight Gain in Fetus With a Decrease in Their Growth CurveFetal Growth Retardation
-
Assistance Publique - Hôpitaux de ParisTerminatedANCA + Vasculitides Relapsing Either Under Corticosteroid | and Immunosuppressant Therapies or After One Year | Post Treatment.France